Contains fulltext : 49190.pdf (publisher's version ) (Closed access)Porin A (PorA), which determines the serosubtype of Neisseria meningitidis, is the main antigen of a candidate vaccine against serogroup B meningococci, which has been shown to induce high-avidity antibodies in children. We characterized the immune response of children after convalescing from meningococcal infection with a serosubtype P1.7-2,4 strain. Acute- and convalescent-phase sera of 21 children with meningococcal septic shock caused by strains with PorA subtype P1.7-2,4 were collected. The serum bactericidal antibody titers, IgG isotype distribution, and antibody avidity were measured. We determined whether the differences in avidity of anti-outer me...
Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for se...
Contains fulltext : 58036.pdf (publisher's version ) (Open Access)Fulminant mening...
Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for se...
Comment in: Toward an Improved Meningococcal Serogroup B Assay. [MBio. 2018]International audienceBi...
Following the introduction of effective protein-polysaccharide conjugate vaccines against capsular g...
Though meningococcal conjugate vaccines are effective against serogroup C, there is currently no vac...
Contains fulltext : 57185.pdf (publisher's version ) (Closed access
Neisseria meningitidis causes 500,000 cases of meningitis and septicaemia annually worldwide, with a...
There is a great need for vaccines against Neisseria meningitidis serogroup B. This is especially im...
In October 1997 a cluster of meningitidis serogroup C infection occurred amongst first year students...
Meningococcal disease is communicable by close contact or droplet aerosols. Striking features are hi...
Contains fulltext : 88187.pdf (publisher's version ) (Open Access)BACKGROUND: In 2...
Neisseria meningitidis causes 500,000 cases of meningitis and septicaemia annually worldwide, with a...
Contains fulltext : 81526.pdf (publisher's version ) (Open Access)T cells may inte...
Contains fulltext : 80183.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for se...
Contains fulltext : 58036.pdf (publisher's version ) (Open Access)Fulminant mening...
Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for se...
Comment in: Toward an Improved Meningococcal Serogroup B Assay. [MBio. 2018]International audienceBi...
Following the introduction of effective protein-polysaccharide conjugate vaccines against capsular g...
Though meningococcal conjugate vaccines are effective against serogroup C, there is currently no vac...
Contains fulltext : 57185.pdf (publisher's version ) (Closed access
Neisseria meningitidis causes 500,000 cases of meningitis and septicaemia annually worldwide, with a...
There is a great need for vaccines against Neisseria meningitidis serogroup B. This is especially im...
In October 1997 a cluster of meningitidis serogroup C infection occurred amongst first year students...
Meningococcal disease is communicable by close contact or droplet aerosols. Striking features are hi...
Contains fulltext : 88187.pdf (publisher's version ) (Open Access)BACKGROUND: In 2...
Neisseria meningitidis causes 500,000 cases of meningitis and septicaemia annually worldwide, with a...
Contains fulltext : 81526.pdf (publisher's version ) (Open Access)T cells may inte...
Contains fulltext : 80183.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for se...
Contains fulltext : 58036.pdf (publisher's version ) (Open Access)Fulminant mening...
Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for se...